研究業績

論文・出版

医師主導治験の実施体制整備状況と課題について:乳癌診療施設に対するアンケート調査(JBCRG-Q06)


JBCRG-Q06 坂東裕子、笠井宏委、青儀健二郎、大谷彰一郎、津川浩一郎、森岡由香、山口ひとみ、吉波哲大、橋本郁子、相馬道郎、戸井雅和、増田慎三、大野真司


乳癌の臨床. 2017 Nov; 32(6): 477-483.

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)


Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi


Cancer Medicine. 2017 Dec; 6(12): 2909-2917.


https://doi.org/10.1002/cam4.1258

アンケート調査からみる医師主導治験の課題と展望


笠井宏委、坂東裕子、青儀健二郎、大野真司


Cancer Board of the Breast. 2017 Aug; 3(2): 52-53(116-117).

Effectiveness of Fulvestrant in Advanced or Metastatic Breast Cancer Patients in the Real World: A Retrospective Multi-center Cohort Study with 1072 Patients (JBCRG-C06; Safari)


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Yutaka Yamamoto, Shinji Ohno and Masakazu Toi


Breast Cancer Research and Treatment. 2017 Jun; 163(3): 545-554. Epub 2017 Mar 23.


https://doi.org/10.1007/s10549-017-4212-x

JBCRGのあらたな取り組み -JCBRGの設立と経緯および臨床試験への取り組み


大野真司


医学のあゆみ. 2017 May; 261(5): 572-576.

Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)


Hiroyasu Yamshiro · Hiroji Iwata · Norikazu Masuda · Naohito Yamamoto · Reiki Nishimura · Shoichiro Ohtani · Nobuaki Sato · Masato Takahashi · Takako Kamio · Kosuke Yamazaki · Tsuyoshi Saito · Makoto Kato · Tecchuu Lee · Shinji Ohno · Katsumasa Kuroi · Toshimi Takano · Masahiro Takada · Shinji Yasuno · Satoshi Morita · Masakazu Toi


International Journal of Clinical Oncology. 2015 Aug; 20(4): 709-722.


https://doi.org/10.1007/s10147-015-0785-8

ネオアジュバント化学療法後の再発リスクが高いホルモン受容体陽性HER2陰性原発性乳癌患者を対象としたサイクリン依存性キナーゼ(CDK)4/6阻害薬palbociclib(PD-0332991)を評価する第III相試験「PENLOPE試験」


岩田 広治


Cancer Board 乳癌. 2014 Dec; 7(2).

ホルモン陽性HER2陰性進行再発乳癌に対する、ホルモン療法による維持療法を利用したベバシズマブ+パクリタキセル療法の治療最適化研究 JBCRG-M04(BOOSTER)


佐治重衡、戸井雅和


Cancer Board 乳癌. 2014 Dec; 7(2).

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer


Norikazu Masuda, Kenji Higaki, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani, Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi


Cancer Chemotherapy and Pharmacology. 2014 Aug; 74(2): 229-38.


https://doi.org/10.1007/s00280-014-2492-y

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)


Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yoichi Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita & Masakazu Toi on behalf of the JBCRG-C03 Collaborative Group


Breast Cancer Research and Treatment. 2014 May; 145(1): 143-53.


https://doi.org/10.1007/s10549-014-2907-9

前のページへ 次のページへ
任意団体JBCRG 研究業績